



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/705,398	11/10/2003	Shutsung Liao	10634-002002 / UCHI 751	4394
26161	7590	02/05/2007	C	
FISH & RICHARDSON PC P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022			EXAMINER BADIO, BARBARA P	
			ART UNIT	PAPER NUMBER
			1617	

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	02/05/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No. 10/705,398	Applicant(s) LIAO ET AL.	
	Examiner Barbara P. Badio, Ph.D.	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 18,20-23,29,31-34,65 and 66 is/are pending in the application.
 4a) Of the above claim(s) 23 and 33 is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 18,20-22,29,31,32 and 65 is/are rejected.
- 7) ☒ Claim(s) 34 and 66 is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date ____. | 6) <input checked="" type="checkbox"/> Other: <u>See Continuation Sheet.</u> |

Continuation of Attachment(s) 6). Other: Raw sequence listing error report.

First Office Action on the Merits of a RCE

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on December 13, 2006 has been entered.

Status of the Application

2. Claims 18, 20-23, 29, 31-34, 65 and 66 are pending in the present application. Claims 23 and 33 stand withdrawn from further consideration as being drawn to a nonelected species. Claims 18, 20-22, 29, 31, 32, 34, 65 and 66 will be examined according to MPEP § 803.02.

3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 102

4. The rejection of claims 18, 20-22, 29, 31, 32 and 65 under 35 USC 102(b) over Kurosawa et al. is withdrawn.

Art Unit: 1617

5. The rejection of claims 18, 20-22, 29, 31, 32 and 65 under 35 USC 102(b) over Cohen-Solal is withdrawn.

6. Claims 18, 20-22, 29, 31 and 32 are rejected under 35 U.S.C. 102(b) as being anticipated by Shen et al. (1990).

Shen et al. teaches several steroid derivatives including (24S)-24-methyl-5 β -cholest-22-ene-3 α ,6 α ,24-triol; 3 α ,6 α -diacetox-24-methyl-5 β -cholest-23-ene-22-one and (22R)-24-methyl-5 β -choles-23-ene-3 α ,6 α ,22-triol (see the entire article, especially page 1766, compounds 4-7). The compounds taught by the reference are encompassed by the instant claims.

7. Claims 18, 20-22, 31 and 32 are rejected under 35 U.S.C. 102(b) as being anticipated by Zhou et al. (1992).

Zhou et al. teaches several steroid derivatives including 3 α ,6 α -dimethoxymethoxy-5 β -25-methyl-choles-22(E)-en-24-one and methyl-22,23-didehydrohyodeoxycholate (see the entire article, especially pages 1839-1840, compounds 11, 12, 22, 25, 26, 27, etc.). The compounds taught by the reference are encompassed by the instant claims.

8. Claims 18, 22, 29, 31, 32 and 65 are rejected under 35 U.S.C. 102(b) as being anticipated by Iorizzi et al. (1995).

Art Unit: 1617

Iorizzi et al. teaches steroid derivatives including 24-methyl-5 α -cholesta-22-en-3 β ,5, 6 β ,15 α ,26-pentaol-26-sulfate, isolated from starfish *Luidia clathrata* and their effect on various bacteria (see the entire article, especially Abstract; page 654, compounds 7, 8, etc.). The compounds and compositions taught by the reference are encompassed by the instant claims.

Claim Objections

9. Claims 34 and 66 are objected to as being dependent upon a rejected base claim.

Note: The claims are allowable to the extent they read on the elected species.

Other Matters

10. Please find enclosed a copy of raw sequence listing error report.


Telephone Inquiry

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Barbara P. Badio, Ph.D. whose telephone number is 571-272-0609. The examiner can normally be reached on M-F from 6:30am-4:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


Barbara P. Badio, Ph.D.
Primary Examiner
Art Unit 1617

BB

February 2, 2007

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING **ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/705,398
Source: LEW 16
Date Processed by STIC: 06/16/2005

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>) , EFS Submission User Manual - ePAVE)**
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**
- 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314**

Revised 01/24/05

Raw Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER: 10/705,398

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics
 Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2 Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 Misaligned Amino
 Numbering The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 Variable Length Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 PatentIn 2.0
 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 Skipped Sequences
 (OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
 (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
 (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
 (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
 This sequence is intentionally skipped

 Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8 Skipped Sequences
 (NEW RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence.
 <210> sequence id number
 <400> sequence id number
 000
- 9 Use of n's or Xaa's
 (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
 Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
 In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10 Invalid <213>
 Response Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11 Use of <220> Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.
 Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
 (See "Federal Register," 05/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 PatentIn 2.0
 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 Misuse of n/Xaa "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid



IFW16

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/705,398

DATE: 06/16/2005

TIME: 12:16:36

Input Set : A:\10634-002002.txt

Output Set: N:\CRF4\06162005\J705398.raw

4 <110> APPLICANT: Liao, Shutsung
 5 Song, Ching
 8 <120> TITLE OF INVENTION: STEROID DERIVATIVES
 11 <130> FILE REFERENCE: 10634-002002
 13 <140> CURRENT APPLICATION NUMBER: US 10/705,398
 C--> 14 <141> CURRENT FILING DATE: 2203-11-10
 16 <150> PRIOR APPLICATION NUMBER: US 09/560,236
 17 <151> PRIOR FILING DATE: 2000-04-28
 19 <150> PRIOR APPLICATION NUMBER: US 60/191,864
 20 <151> PRIOR FILING DATE: 2000-03-24
 22 <150> PRIOR APPLICATION NUMBER: US 60/131,728
 23 <151> PRIOR FILING DATE: 1999-04-30
 26 <160> NUMBER OF SEQ ID NOS: 12
 28 <170> SOFTWARE: FastSEQ for Windows Version 4.0
 30 <210> SEQ ID NO: 1
 31 <211> LENGTH: 16
 32 <212> TYPE: DNA
 33 <213> ORGANISM: Artificial Sequence
 35 <220> FEATURE:
 36 <223> OTHER INFORMATION: Synthetically generated oligonucleotide
 38 <220> FEATURE:
 39 <221> NAME/KEY: misc_feature
 40 <222> LOCATION: 7-10
 41 <223> OTHER INFORMATION: n = a, g, t or c
 43 <400> SEQUENCE: 1
 W--> 44 aggtcannnn aggtca 16
 47 <210> SEQ ID NO: 2
 48 <211> LENGTH: 57
 49 <212> TYPE: DNA
 50 <213> ORGANISM: Artificial Sequence
 52 <220> FEATURE:
 53 <223> OTHER INFORMATION: Synthetically generated oligonucleotide
 55 <220> FEATURE:
 56 <221> NAME/KEY: misc_feature
 57 <222> LOCATION: 16-18, 22-27, 34-39
 58 <223> OTHER INFORMATION: n = a, g, t or c
 60 <400> SEQUENCE: 2
 W--> 61 gtatcgccgg aattcnnntt gnnnnnttg ttgnnnnnnt aagtcgactc tagagcc 57
 63 <210> SEQ ID NO: 3
 64 <211> LENGTH: 57
 65 <212> TYPE: DNA
 66 <213> ORGANISM: Artificial Sequence
 68 <220> FEATURE:

Does Not Comply
Corrected Diskette Needed

(pg-3)

RAW SEQUENCE LISTING

DATE: 06/16/2005

PATENT APPLICATION: US/10/705,398

TIME: 12:16:36

Input Set : A:\10634-002002.txt

Output Set: N:\CRF4\06162005\J705398.raw

```

69 <223> OTHER INFORMATION: Synthetically generated oligonucleotide
71 <220> FEATURE:
72 <221> NAME/KEY: misc_feature
73 <222> LOCATION: 19-24, 31-36, 40-43
74 <223> OTHER INFORMATION: n = a, g, t or c
76 <400> SEQUENCE: 3
W--> 77 ggctctagag tcgacttann nnnncaacaa nnnnnncaan nngaattccg gcgatac 57
79 <210> SEQ ID NO: 4
80 <211> LENGTH: 57
81 <212> TYPE: DNA
82 <213> ORGANISM: Artificial Sequence
84 <220> FEATURE:
85 <223> OTHER INFORMATION: Synthetically generated oligonucleotide
87 <400> SEQUENCE: 4
88 gtatcgccgg aattcatctt gcacagattg ttgcaagaat aagtcgactc tagagcc 57
90 <210> SEQ ID NO: 5
91 <211> LENGTH: 57
92 <212> TYPE: DNA
93 <213> ORGANISM: Artificial Sequence
95 <220> FEATURE:
96 <223> OTHER INFORMATION: Synthetically generated oligonucleotide
98 <400> SEQUENCE: 5
99 ggctctagag tcgacttatt cttgcaacaa tctgtgcaag atgaattccg gcgatac 57
101 <210> SEQ ID NO: 6
102 <211> LENGTH: 60
103 <212> TYPE: DNA
104 <213> ORGANISM: Artificial Sequence
106 <220> FEATURE:
107 <223> OTHER INFORMATION: Synthetically generated oligonucleotide
109 <220> FEATURE:
110 <221> NAME/KEY: misc_feature
111 <222> LOCATION: 16-18, 22-27, 37-42
112 <223> OTHER INFORMATION: n = a, g, t or c
114 <400> SEQUENCE: 6
W--> 115 gtatcgccgg aattcnnntt gnnnnnttgg ttgtgnnnn nntaagtcga ctctagagcc 60
118 <210> SEQ ID NO: 7
119 <211> LENGTH: 60
120 <212> TYPE: DNA
121 <213> ORGANISM: Artificial Sequence
123 <220> FEATURE:
124 <223> OTHER INFORMATION: Synthetically generated oligonucleotide
126 <220> FEATURE:
127 <221> NAME/KEY: misc_feature
128 <222> LOCATION: 19-24, 34-39, 43-45
129 <223> OTHER INFORMATION: n = a, g, t or c
131 <400> SEQUENCE: 7
W--> 132 ggctctagag tcgacttann nnnncaacaa ccannnnnnc aanngaatt ccggcgatac 60
135 <210> SEQ ID NO: 8
136 <211> LENGTH: 5

```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/705,398

DATE: 06/16/2005
TIME: 12:16:36

Input Set : A:\10634-002002.txt
Output Set: N:\CRF4\06162005\J705398.raw

137 <212> TYPE: PRT
138 <213> ORGANISM: Artificial Sequence
140 <220> FEATURE:
141 <223> OTHER INFORMATION: Motif
143 <220> FEATURE:
144 <221> NAME/KEY: VARIANT
145 <222> LOCATION: 2, 3
146 <223> OTHER INFORMATION: Xaa = any amino acid
148 <400> SEQUENCE: 8

*Invalid Response
See Item # 11 in
Summary Sheet*

W--> 149 Leu Xaa Xaa Leu Leu

150 1 5
153 <210> SEQ ID NO: 9
154 <211> LENGTH: 6
155 <212> TYPE: PRT
156 <213> ORGANISM: Artificial Sequence
158 <220> FEATURE:
159 <223> OTHER INFORMATION: Motif
161 <220> FEATURE:
162 <221> NAME/KEY: VARIANT
163 <222> LOCATION: 2, 3
164 <223> OTHER INFORMATION: Xaa = any amino acid
166 <400> SEQUENCE: 9

Same Error

W--> 167 Leu Xaa Xaa Trp Leu Leu

168 1 5
171 <210> SEQ ID NO: 10
172 <211> LENGTH: 26
173 <212> TYPE: DNA
174 <213> ORGANISM: Artificial Sequence
176 <220> FEATURE:
177 <223> OTHER INFORMATION: Synthetically generated oligonucleotide
179 <400> SEQUENCE: 10
180 ttcaggtcac aggaggtcag agagct 26
182 <210> SEQ ID NO: 11
183 <211> LENGTH: 27
184 <212> TYPE: DNA
185 <213> ORGANISM: Artificial Sequence
187 <220> FEATURE:
188 <223> OTHER INFORMATION: Synthetically generated oligonucleotide
190 <400> SEQUENCE: 11
191 tcgagtcctgg tacagggtgt tcttttg 27
193 <210> SEQ ID NO: 12
194 <211> LENGTH: 16
195 <212> TYPE: DNA
196 <213> ORGANISM: Artificial Sequence
198 <220> FEATURE:
199 <223> OTHER INFORMATION: Synthetically generated oligonucleotide
201 <400> SEQUENCE: 12
202 aggtcaagcc aggtca 16

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/705,398

DATE: 06/16/2005
TIME: 12:16:37

Input Set : A:\10634-002002.txt
Output Set: N:\CRF4\06162005\J705398.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; N Pos. 7,8,9,10
Seq#:2; N Pos. 16,17,18,22,23,24,25,26,27,34,35,36,37,38,39
Seq#:3; N Pos. 19,20,21,22,23,24,31,32,33,34,35,36,40,41,42
Seq#:6; N Pos. 16,17,18,22,23,24,25,26,27,30,38,39,40,41,42
Seq#:7; N Pos. 19,20,21,22,23,24,34,35,36,37,38,39,43,44,45
Seq#:8; Xaa Pos. 2,3
Seq#:9; Xaa Pos. 2,3

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/705,398

DATE: 06/16/2005

TIME: 12:16:37

Input Set : A:\10634-002002.txt

Output Set: N:\CRF4\06162005\J705398.raw

L:14 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:44 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0
L:61 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0
L:77 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0
L:115 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0
L:132 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0
L:149 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0
L:167 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0